-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.
GNCA has been the subject of a number of other reports. HC Wainwright downgraded Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th.
Get Genocea Biosciences alerts:Genocea Biosciences Price Performance
Genocea Biosciences stock opened at $0.01 on Wednesday. The firm has a 50 day moving average of $0.01 and a 200 day moving average of $0.47. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Insiders Place Their Bets
In other Genocea Biosciences news, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Paul Edward Walker sold 5,931,843 shares of Genocea Biosciences stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total transaction of $415,229.01. Following the completion of the sale, the insider now owns 4,445,093 shares of the company's stock, valued at $311,156.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ali Behbahani sold 4,445,093 shares of Genocea Biosciences stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total value of $355,607.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,537,612 shares of company stock valued at $781,461. 1.61% of the stock is currently owned by corporate insiders.Institutional Inflows and Outflows
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 59.25% of the company's stock.
About Genocea Biosciences
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Featured Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Institutional Support For TJX Companies May Cap Gains
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新聞網的股票分析師在週三發佈的一份報告中假設了Genocea Biosciences(納斯達克代碼:GNCA-GET Rating)的股票。該公司對這家生物技術公司的股票設定了“賣出”評級。
GNCA has been the subject of a number of other reports. HC Wainwright downgraded Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th.
GNCA一直是其他一些報告的主題。在4月29日週五發佈的一份研究報告中,HC Wainwright將Genocea Biosciences的評級從買入下調至中性。Stifel Nicolaus在4月29日星期五的一份研究報告中將Genocea Biosciences的評級從“買入”下調至“持有”。
Genocea Biosciences Price Performance
Genocea Bioscions價格表現
Genocea Biosciences stock opened at $0.01 on Wednesday. The firm has a 50 day moving average of $0.01 and a 200 day moving average of $0.47. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Genocea Biosciences的股票週三開盤報0.01美元。該公司的50日移動均線切入位在0.01美元,200日移動均線切入位在0.47美元。Genocea Biosciences的12個月低點為0.01美元,12個月高位為2.20美元。該公司的債務權益比為0.24,流動比率為1.35,速動比率為1.35。
Insiders Place Their Bets
內部人士下注
Institutional Inflows and Outflows
機構資金流入和流出
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 59.25% of the company's stock.
一家機構投資者最近提高了對Genocea Biosciences股票的頭寸。根據不列顛國協股票服務公司在最近提交給美國證券交易委員會的13F檔案中的數據,該公司在第四季度增持了Genocea Biosciences,Inc.(納斯達克代碼:GNCA-GET評級)49.4%的股份。該基金持有這家生物技術公司31,981股股票,在此期間又購買了10,576股。截至最近向美國證券交易委員會提交的檔案,不列顛國協股權服務公司擁有Genocea Biosciences公司約0.06%的股份,價值3.7萬美元。對沖基金和其他機構投資者持有該公司59.25%的股票。
About Genocea Biosciences
關於Genocea生物科學
(Get Rating)
(獲取評級)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences,Inc.是一家生物製藥公司,發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS,該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Institutional Support For TJX Companies May Cap Gains
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
- 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
- 對TJX公司的機構支持可能限制漲幅
- 如果你討厭超速攝像頭,那麼你會喜歡Verra Mobility Stock
- 儘管賽諾菲最近跌跌撞撞,但它是買入的嗎?
- 星巴克股票,品牌忠誠度足以成為購買理由嗎
- BJ‘s批發俱樂部流行音樂,Costco會是下一個嗎?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧